AzTrials
AzTrials

AsthmaPhase 1EndomacNCT00839124

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

A Phase 1 study testing Clinical Center Reference Endotoxin (CCRE) in people with Asthma and Hypersensitivity, run by University of North Carolina, Chapel Hill at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This will be a single center, open label study comparing baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with 20,000 EU Clinical Center Reference Endotoxin (CCRE, a component of air pollution)) within each group as well as… Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Asthma, Hypersensitivity
What is being tested?
Clinical Center Reference Endotoxin (CCRE)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteUnited States
Study dates
Jan 2009to Sep 2012
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Normal lung function, defined as (Knudson 1976/1984 predicted set):
  • FVC of > 80 % of that predicted for gender, ethnicity, age and height FEV1 of > 80 % of that predicted for gender, ethnicity, age and height FEV1/FVC ratio of > .75
  • Oxygen saturation of > 94 % and normal blood pressure (Systolic between 150 - 90, Diastolic between 90-60 mm Hg)
  • Symptom Score no greater than 6 (out of a possible 24) for total symptom score with a value no greater than 2 for any one score.
  • Negative methacholine inhalation challenge as performed in the screening protocol. (Less than a 20% decrease in FEV1 at a maximum methacholine concentration of 10 mg/ml)
  • --Negative pregnancy test for females
Show all 12Show fewer
  • Negative allergy skin test (AST)
  • History of episodic wheezing, chest tightness, or shortness of breath after age of 6 years consistent with asthma, or physician diagnosed asthma after age of 6 years.
  • Positive methacholine test.
  • FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of bronchodilating medications for 12 hours)
  • Allergic sensitization to at least one of the following allergen preparations: (House Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1, Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive AST.
  • Negative allergy skin test as performed in the screening protocol.

Who cannot join

  • Any chronic medical condition considered by the PI as a contraindication to the exposure study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, or chronic thyroid disease.
  • Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
  • Use of systemic steroid therapy within the preceding 12 months for an asthma exacerbation. All use of systemic steroids in the last year will be reviewed by a study physician.
  • Use of inhaled steroids, cromolyn or leukotriene inhibitors (montelukast or zafirlukast) except for use of cromolyn exclusively prior to exercise.
  • Use of daily theophylline within the past month.
  • Use of tricyclics and MAO inhibitors
Show all 14Show fewer
  • Pregnancy or nursing a baby.
  • Cigarette smoking > 1 pack per month.
  • Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
  • Exacerbation of asthma more than 2x/week which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
  • Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
  • Viral upper respiratory tract infection within 2 weeks of challenge.
  • Any acute infection requiring antibiotics within 2 weeks of challenge
  • Receipt of LAIV (Live Attenuated Influenza Vaccine), also know as FluMist®, within the prior 14 days

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UNC Center for Environmental Medicine, Asthma and Lung Biology

    Chapel Hill, North Carolina, 27599-7310

Other trials in United States

About this study

Official title: A Study of Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers Compared to Allergic Asthmatic Individuals

This will be a single center, open label study comparing baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with 20,000 EU Clinical Center Reference Endotoxin (CCRE, a component of air pollution)) within each group as well as cross group comparisons between individuals with allergic asthma (AA's)and normal volunteers (NV's). The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers. Secondary objectives include post CCRE comparison between AA's and NV's with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20,000 EU CCRE.

Read the detailed description

This will be a single center, open label study of allergic asthmatic and normal volunteers. The protocol will compare baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with CCRE within each group as well as cross group comparisons between AA's and NV's. The following information indicates procedures to be performed at each visit as well as the anticipated duration of visits. Subsequent to this description are details regarding specific study procedures.

Visit 1: Baseline Visit (5 hours)

  1. Consent will be obtained, review of subject's medical history, current medications and inclusion/exclusion criteria.
  2. Vital sign measurements (temperature, pulse, respiratory rate, blood pressure), oxygen saturation, and symptom scoring
  3. Urine pregnancy test for women of child bearing potential
  4. Spirometry
  5. Venipuncture for CBC with differential and baseline blood analyses
  6. Physical exam of the ears, nose, throat and chest
  7. Collection of exhaled breath for measurement of nitric oxide level
  8. Xenon equilibrium gas scan and MCC
  9. MCC scan
  10. Sputum induction
  11. After completion of the sputum induction, subjects will have brief MCC scan (< 10 minutes)

Visit 2: 24 hours post baseline subjects will return for the following 1 hour visit:

  1. Review any change in medical status over prior 24 hours, vital signs, O2 saturation and symptom score
  2. Follow up MCC scan

Visit 3: 24-48 hours prior to challenge visit at least 2 days after the baseline visit (½ hour)

  1. Review change in medical status since last visit; vital signs, oxygen saturation, \& symptom score
  2. Urine pregnancy test
  3. Spirometry

Visit 4: Endotoxin (CCRE) challenge day (8.5 to 9 hours)

  1. Review any change in medical status since last visit
  2. Vital signs, oxygen saturation, and symptom score
  3. Spirometry
  4. Physical exam of the ears, nose, throat and chest
  5. If above measures are acceptable, CCRE challenge will be performed
  6. Post-challenge monitoring including spirometry, vital signs, oxygen saturation, and symptom score at the following intervals post challenge: 30 and 60 minutes and then hourly for 5 additional hours.
  7. Post challenge venipuncture (blood draw) for CBC with differential and post CCRE blood analyses
  8. Collection of exhaled breath for measurement of nitric oxide level.
  9. Four hours post challenge, subject will have MCC evaluated
  10. After MCC is assessed, sputum induction will be performed.
  11. After completion of the sputum induction, subjects will have brief MCC scan (< 10 minutes)
  12. Discharge home or, alternatively, to GCRC for overnight observation per study MD.

Visit 5: 24 hours post challenge visit (1 hour)

  1. Subject returns to the CEMALB, vital signs, oxygen saturation, and symptom score
  2. Collection of exhaled breath for measurement of nitric oxide level.
  3. Spirometry
  4. Follow-up MCC scan
  5. Each volunteer will be given a symptom scoring sheet for each day up to 96 hours (4 days) after challenge (see accompanying symptom scoring sheet in Appendix 3).

Post Challenge Observations/Reporting (5 minutes)

  1. Subjects will be contacted for phone call follow-up 48-96 hours after challenge (see script Appendix 4 of accompanying protocol)

Study discontinuation visit within 10 days of the challenge dose: (15 minutes)

  1. Vital signs, O2 saturation, symptom score, spirometry
  2. If any findings are abnormal, medical evaluation as directed by the study physician will be undertaken Appendix 1 of the accompanying protocol provides a summary table regarding procedures performed at each subject study visit
Being tested
Clinical Center Reference Endotoxin (CCRE)
Keywords
normal volunteer, healthy control volunteer, healthy subjects, asthma, allergy, allergic asthma
Medical subject headings
Asthma, Hypersensitivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Clinical Center Reference Endotoxin (CCRE)Biological

    Also called air pollution

    inhalation challenge with 20,000 EU CCRE

  • Clinical Center Reference Endotoxin (CCRE)Biological

    Also called air pollution

    inhalation of 20,000 EU CCRE

Study groups in NCT00839124
Study groupRoleWhat they receive
Allergic asthmaActive comparatorsubjects with allergic asthma will undergo challenge with 20,000 EU CCRE
Receives: Biological: Clinical Center Reference Endotoxin (CCRE)
healthy controlActive comparatorHealthy volunteers will undergo challenge with 20,000 EU CCRE
Receives: Biological: Clinical Center Reference Endotoxin (CCRE)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers

    Measured: 6 hours post challenge

Secondary outcomes (1)
  1. Secondary objectives include post CCRE comparison between AA's and NV's with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20,000 EU CCRE.

    Measured: 6-24 hours post challenge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2009 (estimated)
  2. Study startJan 2009
  3. Primary completionSep 2012
  4. Study completionSep 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00839124
Sponsor's protocol ID
08-1750 (CTRC # 2776)
Other IDs
5U19AI077437-02
Acronym
Endomac
Status last verified
Dec 2012
First submitted
6 Feb 2009
Last updated
5 Dec 2012
Results posted
No
Data monitoring committee
Yes

Publications

  • Bennett WD, Alexis NE, Almond M, Herbst M, Zeman KL, Peden DB. Effect of inhaled endotoxin on mucociliary clearance and airway inflammation in mild smokers and nonsmokers. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):459-65. doi: 10.1089/jamp.2013.1089.

    PubMed 24568613
  • Bennett WD, Herbst M, Zeman KL, Wu J, Hernandez ML, Peden DB. Effect of inhaled endotoxin on regional particle deposition in patients with mild asthma. J Allergy Clin Immunol. 2013 Mar;131(3):912-3. doi: 10.1016/j.jaci.2012.09.010. Epub 2012 Oct 25. No abstract available.

    PubMed 23102735

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Clinical Center Reference Endotoxin (CCRE) in people with Asthma and Hypersensitivity, run by University of North Carolina, Chapel Hill at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers (time frame: 6 hours post challenge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00839124, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2012; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in